Hutchison MediPharma Limited, a division of Hutchison China MediTech, has begun a first-in-human Phase I clinical trial of its proprietary anti-inflammatory drug candidate. HMPL-011, a new single-chemical entity with a novel mechanism of action, is a novel cytokine modulator being developed as an oral therapy for auto-immune diseases. The first subjects were dosed on 28 October in Australia, where the trial is being conducted. More details...

Stock Symbol: (AIM: CHM)